Document is current
Any future updates will be listed below
-
Authors
Vu, Therese https://orcid.org/0000-0003-2831-2957
Straube, Jasmin https://orcid.org/0000-0002-1748-0659
Porter, Amy H.
Bywater, Megan
Song, Axia
Ling, Victoria https://orcid.org/0000-0001-9757-1229
Cooper, Leanne
Pali, Gabor
Bruedigam, Claudia
Jacquelin, Sebastien https://orcid.org/0000-0001-5087-3641
Green, Joanne
Magor, Graham
Perkins, Andrew https://orcid.org/0000-0003-3644-7093
Chalk, Alistair M. https://orcid.org/0000-0002-9630-6236
Walkley, Carl R. https://orcid.org/0000-0002-4784-9031
Heidel, Florian H.
Mukhopadhyay, Pamela
Cloonan, Nicole
Gröschel, Stefan
Mallm, Jan-Philipp https://orcid.org/0000-0002-7059-4030
Fröhling, Stefan https://orcid.org/0000-0001-7907-4595
Scholl, Claudia
Lane, Steven W. https://orcid.org/0000-0002-8050-6209
- License Information
-
More Information
Article History
Received: 5 August 2019
Accepted: 28 May 2020
First Online: 15 June 2020
Competing interests
: We have the following disclosures that have been included in the manuscript as potential for conflict of interest. This work was funded by the National Health and Medical Research Fund of Australia and the Leukaemia Foundation of Australia. Celgene provided azacitidine and additional research funding. S.W.L. has participated in an advisory board for Celgene.
